SWOG clinical trial number
CTSU/E2211

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumor

Closed
Phase
Abbreviated Title
Rando Ph II Temozolomide or Temozolomide and Capecitabine in Pts w/Adv Panc Neuroendocrine Tumor
Status Notes
This protocol is closed to accrual effective 3/7/16.
Activated
06/01/2013
Closed
03/07/2016
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Temozolomide Capecitabine

Publication Information Expand/Collapse

2023

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

P Kunz;N Graham;P Catalano;H Nimeri;G Fisher;T Longacre;C Suarez;B Martin;J Yao;M Kulke;A Hendifar;J Shanks;M Shah;M Zalupski;E Schulbach;D Reidy-Lagunes;J Strosberg;P O'Dwyer;A Benson J Clin Oncol. Mar 1;41(7):1359-1369

PMid: PMID36260828 | PMC number: PMC9995105

2018

A Randomized Study of Temozolomide or Temozolomide and Capecitabine in with Advanced Pancreatic Neuroendocrine Tumors: A Trial of the ECOG-ACRIN Cancer Research Group (E2211)

P Kunz;P Catalano;H Nimeiri;G Fisher;T Longacre;C Suarez;J Yao;M Kulke;A Hendifar;J Shanks;M Shah;M Zalupski;E Schmulbach;D Reidy-Lagunes;J Strosberg;P O'Dwyer;A Benson J Clin Oncol 36, 2018 (suppl; abstr 4004; ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
83%
Open
Phase